Zolgensma (onasemnogene abeparvovec-xioi; formerly AVXS-101) is an adeno-associated virus vector-based gene therapy indicated for the treatment of pediatric patients < 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene. Zolgensma is intended to replace the defective SMN1 gene with a functional copy that can create SMN protein, thus preventing the loss of motor neurons and further muscle degeneration in patients with SMA type 1.

If you have a Hayes login, click here to view the full report on the Knowledge Center.